Fosun Pharma Subsidiary Inks $1.85B Deal with Junshi Biosciences for IL-17A Monoclonal Antibody Nokoribai (JS005) in Greater China

Text: Yaoshida

On July 1, Junshi Biosciences issued an announcement confirming that it had entered into a licensing agreement with Jiangsu Wanbang Biopharmaceuticals, a subsidiary of Fosun Pharmaceutical, for its self-developed IL-17A monoclonal antibody.Toripalimab (JS005)The development, registration, manufacturing, and commercialization rights in Greater China (including Hong Kong, Macao, and Taiwan) are fully licensed to Jiangsu Wanbang Biopharmaceuticals.

The financial structure is as follows: Junshi Biosciences takesRMB 215 million down payment(Non-refundable and non-creditable, tax inclusive), with a subsequent maximum ofRMB 1.125 billion milestone,of which R&D milestones amount to RMB 180 million, sales milestones amount to RMB 945 million, plusDouble-digit Percentage Tiered Commission on Net Sales in Greater China, with a total potential market exceeding 1.3 billion.

This drug has a solid foundation. It is Junshi Biosciences’ self-developed specific anti-IL-17A monoclonal antibody, capable of simultaneously binding to both the IL-17A homodimer and the IL-17A/IL-17F heterodimer, thereby blocking downstream inflammatory pathways.

Psoriasis Phase III data are quite impressive; 150 mg group at Week 16PASI 90 Response Rate: 91%, Week 52PASI 100 Response Rate: 65%In December 2025, the New Drug Application (NDA) was accepted by the National Medical Products Administration (NMPA), with the indication being "adult patients with moderate-to-severe plaque psoriasis suitable for systemic therapy or phototherapy"; all subjects in the Phase II clinical trial for ankylosing spondylitis (AS) have completed follow-up, and the program is continuing to advance.

But to be honest, the IL-17A track is nowExtremely CrowdedAccording to statistics from DXY Insight, there are already six approved IL-17A single-target drugs in China: two imported (Novartis’ secukinumab and Eli Lilly’s ixekizumab) and four domestically produced (Akeso’s guncokibart, Hengrui Medicine’s funakizumab, Zhixiang Jintai’s sailicizumab, and 3SBio’s anmokizumab). UCB’s IL-17A/F dual-target drug (bimekizumab) surged into the global top 100 pharmaceutical companies by sales in 2025, with a year-on-year growth rate of 285%.

Junshi Biosciences’ NDA submission is actually lagging behind; relying on its own commercialization efforts to compete with Novartis, Eli Lilly, and a host of Chinese-made products in terms of distribution channels may not offer a high cost-performance ratio.

Thus, the logic behind this collaboration is clear: Junshi Biosciences has entrusted the commercialization of psoriasis, its "lead indication," to Fosun Pharmaceutical. Fosun possesses a mature clinical development and commercialization infrastructure in autoimmune diseases (particularly psoriasis), with the capacity to effectively manage distribution channels, hospital listings, and national medical insurance negotiations.

Junshi Biosciences is recouping over RMB 200 million in upfront payments plus subsequent milestones, reallocating resources to more core pipelines such as PD-1, BTLA, and Claudin18.2 ADC, while continuing to leverage Fosun Pharmaceutical’s development capabilities to advance other indications like AS.

For Fosun Pharmaceutical, this represents another strategic piece added to its autoimmune portfolio, following its acquisition in 2025 of the promotional rights for Zhixiang Jintai’s Slevimab (a bispecific antibody for rabies). In the therapeutic areas of psoriasis and ankylosing spondylitis, Fosun’s ambition appears to extend beyond merely “selling a single drug”; rather, it aims to leverage its pipeline to develop a combination-based commercial strategy.

The next two key nodes to watch are: first, when the NMPA will approve the New Drug Application (NDA) for nocobartemab (given the December acceptance timeline, a decision is highly likely within 2026); and second, whether Fosun Pharmaceutical can drive sales volume for this drug, which boasts solid data but enters the market late, by leveraging its distribution channels and pricing strategies in the already saturated IL-17A market.

Disclaimer: The content of this official account is intended to provide industry updates for professionals in the pharmaceutical and healthcare sectors. It does not constitute any medical, medication, drug purchase, or investment advice. The completeness and accuracy of the content are not guaranteed. Your access to this content does not imply that you are an intended recipient of this official account. Please read with caution.

Follow our official account for reliable, professional news and analysis.